Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists do not uniformly increase blood pressure; in fact, clinical trials show modest blood pressure reductions in many patients, though responses vary significantly. Individual metabolic factors, baseline cardiovascular health, and genetic predispositions influence how each person's body responds to GLP-1 therapy.

For patients considering compounded GLP-1 medications, understanding your unique cardiovascular profile and genetic context is essential. PlexusDx supports precision wellness by combining clinical evidence with biomarker and genetic insights, helping you and your provider evaluate whether GLP-1 therapy aligns with your individual health goals and cardiovascular status.

Start your GLP-1 program with PlexusDx

One all-inclusive price covers your online provider visit, prescription, compounded medication, and shipping — no membership, no hidden fees. Complete a short intake and a licensed provider takes it from there.

Start your intake →

Blood Pressure Trends in GLP-1 Clinical Trials

Large randomized controlled trials of GLP-1 receptor agonists demonstrate systolic blood pressure reductions averaging 2–4 mmHg in patients with and without type 2 diabetes. The LEADER trial (liraglutide) and SUSTAIN-6 trial (semaglutide) both showed modest but statistically significant reductions in cardiovascular events, partly attributed to blood pressure and weight improvements.

However, individual responses are heterogeneous. Some patients experience no change, while others report reductions of 10–15 mmHg or greater. Weight loss magnitude, baseline hypertension status, and concurrent antihypertensive medication use all influence blood pressure outcomes during GLP-1 therapy.

Key Cardiovascular Biomarkers and GLP-1 Response Patterns

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to GLP-1 medications or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Biomarker/Factor Clinical Relevance to GLP-1 BP Response
Baseline Systolic BP Hypertensive patients may experience greater absolute BP reductions than normotensive individuals; those on multiple antihypertensive agents require closer monitoring.
BMI and Weight Status Patients with higher baseline BMI often achieve greater weight loss, which correlates with more pronounced blood pressure reductions during GLP-1 therapy.
Heart Rate Response GLP-1 drugs may increase resting heart rate by 2–4 bpm; this effect varies by individual and is generally considered benign, though it warrants monitoring in susceptible patients.
Renal Function and Proteinuria GLP-1 therapy reduces proteinuria and slows renal disease progression; improved kidney function supports overall cardiovascular stability and blood pressure regulation.

Genetic Predispositions and Individual GLP-1 Receptor Sensitivity

Genetic variation in the GLP-1 receptor (GLP1R) and related metabolic pathways influences how efficiently your cells respond to GLP-1 therapy. Variants in genes like MC4R rs17782313 may modulate appetite regulation, weight loss, and blood pressure responses to GLP-1 medications.

The Precision Peptide Genetic Test examines key predispositions in GLP-1 and related metabolic pathways. Understanding these genetic factors may help provide context for why two patients on the same GLP-1 dose may experience different blood pressure and metabolic outcomes, supporting more informed conversations with your healthcare provider.

Who Should Monitor Blood Pressure Closely During GLP-1 Therapy

Patients with existing hypertension, particularly those on multiple antihypertensive medications, require closer blood pressure monitoring when initiating or adjusting GLP-1 doses. Rapid weight loss may enhance the effects of existing medications, potentially requiring dose adjustments to prevent hypotension.

Individuals with a history of diabetic kidney disease, cardiovascular disease, or orthostatic hypotension should discuss GLP-1 therapy with a qualified healthcare provider before starting. Your medical history, current medications, and cardiovascular biomarkers all inform whether GLP-1 is appropriate and what monitoring frequency is needed.

How PlexusDx Supports a More Personalized Approach

PlexusDx genetic and biomarker insights may help provide context for your individual blood pressure response to GLP-1 therapy. The Precision Peptide Genetic Test reveals predispositions in key GLP-1 receptor pathways and metabolic genes, including MC4R rs17782313, and FTO rs9939609, which influence weight loss magnitude and metabolic regulation. This genetic information should be interpreted with a qualified healthcare provider as part of a comprehensive assessment.

The Precision Peptide Genetic Test does not predict your exact blood pressure response to a specific GLP-1 medication. Rather, it identifies genetic predispositions in peptide pathways that correlate with variations in weight loss, appetite regulation, and metabolic outcomes. These predispositions may inform why some patients achieve greater therapeutic benefit than others, but individual response remains influenced by many environmental, behavioral, and clinical factors.

Combining your genetic predisposition data with your current biomarkers—baseline blood pressure, BMI, cardiovascular history, and kidney function—can support a more personalized conversation with your provider about GLP-1 therapy selection, dosing strategy, and monitoring plan. PlexusDx compounded semaglutide and tirzepatide options are available at multiple dose strengths, allowing providers to tailor initiation and titration protocols to your individual profile.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Do GLP-1 medications raise blood pressure or lower it?

The article says they do not uniformly raise it, and that large randomized controlled trials show systolic reductions averaging 2 to 4 mmHg in patients with and without type 2 diabetes. It notes responses are heterogeneous, with some people seeing no change and others reporting reductions of 10 to 15 mmHg or more. Weight loss magnitude and baseline hypertension status both shape the outcome.

Which cardiovascular outcome trials does the article cite on blood pressure?

The article names the LEADER trial with liraglutide and the SUSTAIN-6 trial with semaglutide, saying both showed modest but statistically significant reductions in cardiovascular events. It attributes part of that benefit to improvements in blood pressure and weight rather than to blood pressure alone. It presents the effect as an association observed in trial populations.

Does the article say GLP-1 therapy affects resting heart rate?

Yes. The article's table says GLP-1 drugs may increase resting heart rate by 2 to 4 beats per minute, that the effect varies by individual, and that it is generally considered benign though it warrants monitoring in susceptible patients. That row sits alongside entries on baseline systolic pressure, BMI and weight status, and renal function.

Why might someone already on blood pressure medication need closer monitoring?

The article says patients with existing hypertension, especially those taking multiple antihypertensive medications, need closer monitoring when starting or adjusting GLP-1 therapy. Its reasoning is that rapid weight loss may enhance the effect of the existing medications, potentially requiring adjustments to prevent hypotension. Those adjustments are decisions for the prescribing clinician, not for the patient to make alone.

What does the article say about GLP-1 therapy and kidney measures?

The article's table states that GLP-1 therapy reduces proteinuria and slows renal disease progression, and it links improved kidney function to overall cardiovascular stability and blood pressure regulation. Separately it lists a history of diabetic kidney disease, cardiovascular disease, or orthostatic hypotension as reasons to discuss therapy with a qualified provider before starting.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves